KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Cost of Revenue (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Cost of Revenue for 18 consecutive years, with $296.0 million as the latest value for Q1 2026.

  • For Q1 2026, Cost of Revenue rose 48.89% year-over-year to $296.0 million; the TTM value through Mar 2026 reached $950.0 million, down 5.97%, while the annual FY2025 figure was $959.9 million, 11.72% down from the prior year.
  • Cost of Revenue hit $296.0 million in Q1 2026 for Regeneron Pharmaceuticals, up from $137.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $326.8 million in Q4 2024 and bottomed at $137.8 million in Q4 2025.
  • Average Cost of Revenue over 5 years is $224.0 million, with a median of $212.5 million recorded in 2023.
  • Year-over-year, Cost of Revenue crashed 70.63% in 2022 and then surged 55.47% in 2024.
  • Regeneron Pharmaceuticals' Cost of Revenue stood at $238.4 million in 2022, then dropped by 11.83% to $210.2 million in 2023, then soared by 55.47% to $326.8 million in 2024, then crashed by 57.83% to $137.8 million in 2025, then skyrocketed by 114.8% to $296.0 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $296.0 million, $137.8 million, and $240.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.